// App-Quantinova.ai

TPS8069 : KEYNOTE-185: a randomized, open-label phase 3 study of pembrolizumab in combination with lenalidomide and low-dose dexamethasone in newly diagnosed and treatment-naive multiple myeloma (MM).

Researchers

Presenter

  • Antonio Palumbo

Principal Investigators

  • Maria-Victoria Mateos

  • Jesus San Miguel

  • Jatin Shah

  • Seth Thompson

  • Patricia Maria Marinello

  • Sundar Jagannath

Medical Centers

  • University of Turin, Turin, Italy

  • University Hospital of Salamanca, Salamanca, Spain

  • University of Navarra, Pamplona, Spain

  • The University of Texas MD Anderson Cancer Canter, Houston, TX

  • Merck & Co., Inc., Kenilworth, NJ

  • Mount Sinai Medical Center, New York, NY

Locations

  • United States

  • Spain

  • Italy

Companies

  • Merck & Co., Inc.

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Multiple Myeloma

Biomarkers

  • N/A

Drug/Treatment

  • Dexamethasone

  • Dekpak 13 Day Taperpak

  • Pembrolizumab

  • Lenalidomide

Outcome

  • N/A

Study Design

  • Randomized

  • Double Blind/Blinded

  • Open Label

  • Multinational

Phase

  • III

Study Id's

  • NCT02579863

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved